Compare BridgeBio Pharma Inc (BBIO) vs KraneShares Hang Seng TECH Index ETF (KTEC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs KraneShares Hang Seng TECH Index ETF — how do they compare? BridgeBio Pharma Inc trades at $83.9 (market cap $16.61B), while KraneShares Hang Seng TECH Index ETF trades at $13.5. The key difference: BridgeBio Pharma Inc is trading nearer its 52-week high, KraneShares Hang Seng TECH Index ETF nearer its low. Which is the better fit depends on your goals.
| BBIO | KTEC | |
|---|---|---|
Market Cap | $16.61B | — |
Sector | Health | Sector/Thematic |
52-Week High | $90.17 | $19.51 |
52-Week Low | $47.29 | $12.00 |
Enterprise Value | $18.16B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $84.48, up 2.03% with bullish technical signals from moving averages. Despite strong revenue growth from $222M in 2024 to $502M in 2025, the company reports significant losses with a -144.39% net margin. Recent FDA acceptance for encaleret in ADH1 and Attruby's commercial expansion in ATTR-CM provide growth catalysts, though cash flow remains negative at -$111M in 2025.
The stock presents high-risk growth potential with 88% analyst buy ratings and $102.20 consensus target, but faces substantial execution risks from ongoing losses and $1.72B debt load. Success hinges on pipeline approvals and Attruby's market penetration, making it suitable for risk-tolerant investors betting on biotech breakthroughs.
KTEC trades at $13.78, up 1.47% today, with a bullish technical signal driven by moving averages. Support and resistance cluster at $14, indicating a critical price zone. Financial ratios are unavailable, limiting fundamental clarity. Recent news highlights China's AI competition as a potential catalyst for tech ETFs like KTEC.
The stock's outlook hinges on AI sector momentum, but risks include reliance on thematic trends and lack of disclosed financials. Upside depends on broader tech ETF inflows, while volatility from geopolitical or market shifts poses a near-term challenge.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About KraneShares Hang Seng TECH Index ETF
KTEC tracks the Hang Seng TECH Index, providing targeted exposure to the 30 largest technology companies listed on the Hong Kong Stock Exchange. It focuses on innovative, internet-based businesses across sectors like e-commerce, fintech, cloud computing, and digital technology.
Read more on KTEC →
